Impact of metformin use during pregnancy on fetal congenital malformations across 11 organ systems: a meta-analysis and drug-target Mendelian randomization study
Abstract
Aims: Metformin is a cost-effective alternative to insulin for gestational diabetes mellitus (GDM), yet concerns regarding potential teratogenicity persist. This study aimed to evaluate the association between prenatal metformin exposure and multisystem congenital malformations (CMs), and to explore biologically relevant pathways.
Methods: This study first conducted a meta-analysis of RCTs and cohort studies assessing maternal metformin use and fetal CMs. Subsequently, drug-target Mendelian randomization (DTMR) examined genetically proxied associations between metformin pharmacodynamic targets (eQTLs) and 64 CMs (FinnGen), reflecting lifelong target perturbation, adjusting for maternal confounders and validating with placental eQTL data.
Results: Meta-analysis showed a protective effect of metformin versus insulin on overall CMs (RR = 0.83, 95% CI 0.71-0.99). In DTMR, following Bonferroni correction and covariate adjustment, seven of 92 target genes (e.g., NDUFS5, NDUFA2) showed significant associations, primarily exhibiting protective effects against circulatory and musculoskeletal system. Validation in placental eQTLs corroborated the direction of effects for 17 gene-outcome pairs, reinforcing the robustness of key safety signals.
Conclusion: By integrating clinical and genetic evidence, this study is consistent with the overall clinical safety of metformin use during pregnancy with respect to congenital malformations and provides hypothesis-generating insights into…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.